International Journal of Hematology

, Volume 97, Issue 5, pp 581–598

Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies

Review Article

DOI: 10.1007/s12185-013-1313-0

Cite this article as:
Wahid, S.F.A. Int J Hematol (2013) 97: 581. doi:10.1007/s12185-013-1313-0


Hematopoietic stem cell transplantation (HCT) utilizing non-myeloablative (NMA) and reduced-intensity conditioning (RIC) regimens (collectively referred to as reduced-toxicity HCT, RT-HCT) has become a viable therapeutic option for patients with hematological malignancies who are ineligible for standard myeloablative conditioning transplantation (MA-HCT). RT-HCT has been shown to induce stable engraftment with low toxicity, and to produce similar overall and progression-free survival (PFS) when compared to MA-HCT in acute myeloid leukemia and myelodysplastic syndrome. The best results for RT-HCT have been reported for patients with disease that is in remission, indolent and chemosensitive, and with a strong graft-versus-malignancy effect. Chronic graft-versus-host disease seems to correlate with a lower relapse rate and better PFS. RT-HCT is inferior when performed in poor risk or advanced disease, due to high relapse rates. A search for novel strategies that includes the most appropriate conditioning regimens and post-transplant immunomodulation protocols with more intensive anti-malignancy activity but limited toxicity is in progress. This review provides an update on the results of clinical studies of RT-HCT, and discusses possible indications and investigative strategies for improving the clinical outcomes of RT-HCT for the major hematological malignancies.


Reduced-intensity conditioning (RIC) Non-myeloablative (NMA) regimen Hematological malignancies (HM) Reduced-toxicity hematopoietic stem cell transplantation (RT-HCT) Graft-versus-malignancy (GvM) Transplantation-related mortality (TRM) Transplant-related toxicities (TRT) 

Copyright information

© The Japanese Society of Hematology 2013

Authors and Affiliations

  1. 1.Department of Medicine, Cell Therapy Centre, Faculty of MedicineUniversiti Kebangsaan Malaysia Medical Centre (UKMMC)Kuala LumpurMalaysia

Personalised recommendations